Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma

Don Eslin, Umesh Tanaji Sankpal, Chris Lee, Robert M. Sutphin, Pius Maliakal, Erika Currier, Giselle Sholler, Moeez Khan, Riyaz Mahammad Basha

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Current therapeutic options for recurrent neuroblastoma have poor outcomes that warrant the development of novel therapeutic strategies. Specificity protein (Sp) transcription factors regulate several genes involved in cell proliferation, survival, and angiogenesis. Sp1 regulates genes believed to be important determinants of the biological behavior of neuroblastoma. Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug, is known to induce the degradation of Sp proteins and may serve as a novel anti-cancer agent. The objective of this investigation was to examine the anti-cancer activity of TA using established human neuroblastoma cell lines. We tested the anti-proliferative effect of TA using SH-SY5Y, CHLA90, LA1 55n, SHEP, Be2c, CMP 13Y, and SMS KCNR cell lines. Cells were treated with TA (0/25/50/100μM) and cell viability was measured at 24, 48, and 72h post-treatment. Selected neuroblastoma cell lines were treated with 50μM TA for 24 and 48h and tested for cell apoptosis using Annexin-V staining. Caspase activity was measured with caspase 3/7 Glo kit. Cell lysates were prepared and the expression of Sp1, survivin, and c-PARP were evaluated through Western blot analysis. TA significantly inhibited the growth of neuroblastoma cells in a dose/time-dependent manner and significantly decreased Sp1 and survivin expression. Apart from cell cycle (G0/G1) arrest, TA caused significant increase in the apoptotic cell population, caspase 3/7 activity, and c-PARP expression. These results show that TA effectively inhibits neuroblastoma cell growth potentially through suppressing mitosis, Sp1, and survivin expression, and inducing apoptosis. These results show TA as a novel therapeutic agent for neuroblastoma.

Original languageEnglish
Pages (from-to)377-386
Number of pages10
JournalMolecular Carcinogenesis
Volume52
Issue number5
DOIs
StatePublished - 1 May 2013

Fingerprint

Neuroblastoma
Cell Proliferation
Apoptosis
Caspase 7
Therapeutics
Cell Line
Caspase 3
Cell Survival
Sp Transcription Factors
G1 Phase Cell Cycle Checkpoints
Cytidine Monophosphate
tolfenamic acid
Annexin A5
Growth
Caspases
Mitosis
Proteolysis
Genes
Neoplasms
Anti-Inflammatory Agents

Keywords

  • NSAID
  • Pediatric tumors
  • Sp1
  • Survivin
  • Transcription factors

Cite this

Eslin, Don ; Sankpal, Umesh Tanaji ; Lee, Chris ; Sutphin, Robert M. ; Maliakal, Pius ; Currier, Erika ; Sholler, Giselle ; Khan, Moeez ; Basha, Riyaz Mahammad. / Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis : A novel therapeutic agent for neuroblastoma. In: Molecular Carcinogenesis. 2013 ; Vol. 52, No. 5. pp. 377-386.
@article{25d90bb9fe134085abb90a4a50381741,
title = "Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma",
abstract = "Current therapeutic options for recurrent neuroblastoma have poor outcomes that warrant the development of novel therapeutic strategies. Specificity protein (Sp) transcription factors regulate several genes involved in cell proliferation, survival, and angiogenesis. Sp1 regulates genes believed to be important determinants of the biological behavior of neuroblastoma. Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug, is known to induce the degradation of Sp proteins and may serve as a novel anti-cancer agent. The objective of this investigation was to examine the anti-cancer activity of TA using established human neuroblastoma cell lines. We tested the anti-proliferative effect of TA using SH-SY5Y, CHLA90, LA1 55n, SHEP, Be2c, CMP 13Y, and SMS KCNR cell lines. Cells were treated with TA (0/25/50/100μM) and cell viability was measured at 24, 48, and 72h post-treatment. Selected neuroblastoma cell lines were treated with 50μM TA for 24 and 48h and tested for cell apoptosis using Annexin-V staining. Caspase activity was measured with caspase 3/7 Glo kit. Cell lysates were prepared and the expression of Sp1, survivin, and c-PARP were evaluated through Western blot analysis. TA significantly inhibited the growth of neuroblastoma cells in a dose/time-dependent manner and significantly decreased Sp1 and survivin expression. Apart from cell cycle (G0/G1) arrest, TA caused significant increase in the apoptotic cell population, caspase 3/7 activity, and c-PARP expression. These results show that TA effectively inhibits neuroblastoma cell growth potentially through suppressing mitosis, Sp1, and survivin expression, and inducing apoptosis. These results show TA as a novel therapeutic agent for neuroblastoma.",
keywords = "NSAID, Pediatric tumors, Sp1, Survivin, Transcription factors",
author = "Don Eslin and Sankpal, {Umesh Tanaji} and Chris Lee and Sutphin, {Robert M.} and Pius Maliakal and Erika Currier and Giselle Sholler and Moeez Khan and Basha, {Riyaz Mahammad}",
year = "2013",
month = "5",
day = "1",
doi = "10.1002/mc.21866",
language = "English",
volume = "52",
pages = "377--386",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "5",

}

Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis : A novel therapeutic agent for neuroblastoma. / Eslin, Don; Sankpal, Umesh Tanaji; Lee, Chris; Sutphin, Robert M.; Maliakal, Pius; Currier, Erika; Sholler, Giselle; Khan, Moeez; Basha, Riyaz Mahammad.

In: Molecular Carcinogenesis, Vol. 52, No. 5, 01.05.2013, p. 377-386.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis

T2 - A novel therapeutic agent for neuroblastoma

AU - Eslin, Don

AU - Sankpal, Umesh Tanaji

AU - Lee, Chris

AU - Sutphin, Robert M.

AU - Maliakal, Pius

AU - Currier, Erika

AU - Sholler, Giselle

AU - Khan, Moeez

AU - Basha, Riyaz Mahammad

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Current therapeutic options for recurrent neuroblastoma have poor outcomes that warrant the development of novel therapeutic strategies. Specificity protein (Sp) transcription factors regulate several genes involved in cell proliferation, survival, and angiogenesis. Sp1 regulates genes believed to be important determinants of the biological behavior of neuroblastoma. Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug, is known to induce the degradation of Sp proteins and may serve as a novel anti-cancer agent. The objective of this investigation was to examine the anti-cancer activity of TA using established human neuroblastoma cell lines. We tested the anti-proliferative effect of TA using SH-SY5Y, CHLA90, LA1 55n, SHEP, Be2c, CMP 13Y, and SMS KCNR cell lines. Cells were treated with TA (0/25/50/100μM) and cell viability was measured at 24, 48, and 72h post-treatment. Selected neuroblastoma cell lines were treated with 50μM TA for 24 and 48h and tested for cell apoptosis using Annexin-V staining. Caspase activity was measured with caspase 3/7 Glo kit. Cell lysates were prepared and the expression of Sp1, survivin, and c-PARP were evaluated through Western blot analysis. TA significantly inhibited the growth of neuroblastoma cells in a dose/time-dependent manner and significantly decreased Sp1 and survivin expression. Apart from cell cycle (G0/G1) arrest, TA caused significant increase in the apoptotic cell population, caspase 3/7 activity, and c-PARP expression. These results show that TA effectively inhibits neuroblastoma cell growth potentially through suppressing mitosis, Sp1, and survivin expression, and inducing apoptosis. These results show TA as a novel therapeutic agent for neuroblastoma.

AB - Current therapeutic options for recurrent neuroblastoma have poor outcomes that warrant the development of novel therapeutic strategies. Specificity protein (Sp) transcription factors regulate several genes involved in cell proliferation, survival, and angiogenesis. Sp1 regulates genes believed to be important determinants of the biological behavior of neuroblastoma. Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug, is known to induce the degradation of Sp proteins and may serve as a novel anti-cancer agent. The objective of this investigation was to examine the anti-cancer activity of TA using established human neuroblastoma cell lines. We tested the anti-proliferative effect of TA using SH-SY5Y, CHLA90, LA1 55n, SHEP, Be2c, CMP 13Y, and SMS KCNR cell lines. Cells were treated with TA (0/25/50/100μM) and cell viability was measured at 24, 48, and 72h post-treatment. Selected neuroblastoma cell lines were treated with 50μM TA for 24 and 48h and tested for cell apoptosis using Annexin-V staining. Caspase activity was measured with caspase 3/7 Glo kit. Cell lysates were prepared and the expression of Sp1, survivin, and c-PARP were evaluated through Western blot analysis. TA significantly inhibited the growth of neuroblastoma cells in a dose/time-dependent manner and significantly decreased Sp1 and survivin expression. Apart from cell cycle (G0/G1) arrest, TA caused significant increase in the apoptotic cell population, caspase 3/7 activity, and c-PARP expression. These results show that TA effectively inhibits neuroblastoma cell growth potentially through suppressing mitosis, Sp1, and survivin expression, and inducing apoptosis. These results show TA as a novel therapeutic agent for neuroblastoma.

KW - NSAID

KW - Pediatric tumors

KW - Sp1

KW - Survivin

KW - Transcription factors

UR - http://www.scopus.com/inward/record.url?scp=84876143720&partnerID=8YFLogxK

U2 - 10.1002/mc.21866

DO - 10.1002/mc.21866

M3 - Article

C2 - 22213339

AN - SCOPUS:84876143720

VL - 52

SP - 377

EP - 386

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 5

ER -